Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Akebia Therapeutics posts robust Q4 results, eyes expansion opportunities

Akebia Therapeutics showcased a strong performance in Q4 2022, highlighting revenue growth, regulatory progress, and strategic initiatives. The company faces challenges in regulatory processes and funding but is well-positioned to capitalize on opportunities for growth and innovation.

Akebia Therapeutics excels in Q1 2023, faces regulatory challenges

Akebia Therapeutics demonstrated strong performance in Q1 2023 with key achievements in product approvals and clinical study results, while also addressing revenue challenges and cost management.
The company faces challenges related to regulatory compliance and revenue decline but has opportunities to explore new therapeutic applications and strategic partnerships for growth.
Overall, Akebia's proactive approach to addressing challenges and pursuing opportunities positions it well for future success in the competitive biopharmaceutical market.

Akebia Therapeutics advances vadadustat globally, eyes U.S. launch in 2024

Akebia Therapeutics showcased operational progress and financial stability during the Q2 earnings call, emphasizing vadadustat's global potential.
While facing regulatory challenges and competitive pressures, the company's strategic partnerships and leadership confidence signal growth opportunities.
Analysts' inquiries highlighted areas for improvement, suggesting a need for clearer communication and strategic clarity in key operational areas.
Overall, Akebia remains focused on advancing vadadustat towards potential U.S. approval, positioning for future growth and market success.

Akebia Therapeutics reports strong Q3 earnings and readies for vadadustat launch

Akebia Therapeutics is poised for the potential launch of vadadustat with strong financial performance and a well-prepared commercial infrastructure.
The company faces challenges in pricing strategies and market competition but has opportunities to capture a significant share of the anemia treatment market.
Overall, Akebia Therapeutics remains focused on delivering value to patients and shareholders through vadadustat's potential success in the U.S. market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Volitionrx Limited

Exicure Inc

Insiders are buying these penny stocks but are they worth the risk? The post 3 Top Penny Stocks To Buy According To Insiders Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Buy According To Insiders Before 2023

Bone Biologics Corp

Hillstream Biopharma

HTG Molecular Diagnostics

Kalera PLC

Pagaya Technologies Ltd

SINTX Technologies Inc

Sio Gene Therapies

Venator Materials

Wearable Devices Ltd

Penny stocks to watch trading under $1 right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch

The Beachbody Co.

ComSovereign Holding

Faraday Future Intelligent Electric

Nymox Pharmaceutical

Rigel Pharmaceuticals

Sonim Technologies Inc

Statera Biopharma Inc

Tricida Inc

Titan Medical Inc

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 This Week

CAMBRIDGE, Mass. , Nov. 22, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022 in New York City, New York.

Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates

Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Mercedes Carrasco - Senior Director of Corporate Communications John Butler - CEO, President and Director David Spellman - Senior VP, CFO and Treasurer Conference Call Participants Allison Bratzel - Piper Sandler Thomas Yip - H.C. Wainwright Operator Good day and thank you for standing by.

Akebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call Transcript

Akebia to host conference call on November 3 at 4:30 p.m. ET   Filed Formal Dispute Resolution Request related to the CRL for vadadustat Reported Auryxia® (ferric citrate) quarterly net product revenue of $42.2, an increase of 14.9% over Q3 2021 Affirmed 2022 Auryxia net product revenue guidance of $170 - $175M Managed operating expenses in support of three strategic pillars CAMBRIDGE, Mass.

Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Akebia to Host Conference Call to Provide Business Update CAMBRIDGE, Mass. , Oct. 27, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2022 on Thursday, November 3, 2022 following the close of financial markets.

Akebia Therapeutics to Report Third Quarter Financial Results and Highlight Recent Company Milestones

CAMBRIDGE, Mass. , Oct. 21, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2022 (ASN Kidney Week 2022), which will take place in Orlando, November 3-6, 2022.

Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022

CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C.

Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

Akebia Therapeutics Inc. (NASDAQ:AKBA ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Mercedes Carrasco - Senior Director of Corporate Communications John Butler - CEO, President and Director Steve Burke - Senior VP of Research and Development and Chief Medical Officer David Spellman - Senior VP, CFO and Treasurer Conference Call Participants Allison Bratzel - Piper Sandler Operator Hello, and welcome to the Akebia Second Quarter 2022 Financial Results. [Operator Instructions] Please note this event is being recorded.

Akebia Therapeutics Inc. (AKBA) CEO John Butler on Q2 2022 Results - Earnings Call Transcript

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates

Akebia to host conference call on August 4 at 4:30 p.m. ET Reported net Auryxia® (ferric citrate) product revenue of $43.7M, a 32.4% increase over Q2 2021 Increased 2022 net Auryxia product revenue guidance to $170 - $175M Regained full rights to vadadustat in the U.S., Europe and other markets Delivered a decrease in operating expenses supporting its three strategic pillars Shared initial findings from investigator-sponsored study evaluating vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in patients with COVID-19 and hypoxemia CAMBRIDGE, Mass.

Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass. , Aug. 4, 2022 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an investigator-sponsored study evaluating vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the prevention and treatment of ARDS in clinical trial subjects with COVID-19 and hypoxemia (O2 saturation ≤94%).

Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)

Akebia to Host Conference Call to Provide Business Update CAMBRIDGE, Mass. , July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2022 on Thursday, August 4, 2022 following the close of financial markets.

Akebia Therapeutics to Report Second Quarter Financial Results

Oatly

Verrica Pharmaceuticals Inc

Check these penny stocks out for your watchlist The post Hot Penny Stocks to Buy Now? 3 to Watch in Early July  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Buy Now? 3 to Watch in Early July

Akebia Therapeutics (AKBA) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat. The post Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?

Quoin Pharmaceuticals Ltd

Ricebran Technologies

Shift Technologies

Penny stocks under $1 to watch. The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 4 To Watch Under $1

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday.

Akebia Therapeutics And 20 Stocks Moving Premarket

Micron Technology

Accolade

Costco

Hillenbrand

Some of the stocks that may grab investor focus today are: Micron Technology Inc (NASDAQ: MU) reported upbeat financial results for its third quarter, but issued weak guidance for its fourth quarter. Micron shares dropped 1.4% to $54.50 in the after-hours trading session.

Micron, Akebia Therapeutics And 3 Stocks To Watch Heading Into Friday

Akebia Therapeutics Inc (NASDAQ: AKBA) shares are surging in Thursday's after-hours session after the company executed an agreement to terminate its Vadadustat collaboration and license agreements with Otsuka Pharmaceutical. As a result of the termination of the agreements, Akebia.

Why Akebia Therapeutics Stock Is Soaring After Hours

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia Akebia to assume responsibility for regulatory review processes previously led by Otsuka CAMBRIDGE, Mass. , June 30, 2022 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical Co., Ltd.

Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka

AKBA stock is up big, but the lack of news is concerning considering that Akebia Therapeutics already faces a regulatory setback. The post Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News appeared first on InvestorPlace.

Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News

Digital Brands Group Inc

Exela Technologies

Here's what you need to know about trading penny stocks today The post What to Know About Trading Penny Stocks on June 13th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Trading Penny Stocks on June 13th

Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated.

Why Are Akebia Therapeutics Shares Falling Today?

News for Akebia Therapeutics Stock (AKBA)